Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5

Conditions

Glioblastoma 5Glioma 4Brain Neoplasms 4Recurrence 1

Interventions

Temozolomide 165Magnetic Resonance Spectroscopy 130Radiotherapy 95Specimen Handling 80Radiosurgery 60Cyclophosphamide 55pembrolizumab 51Bevacizumab 51Nivolumab 48Radiation 47Carboplatin 34Biopsy 33Irinotecan 29Lomustine 25Etoposide 25Vincristine 23Topotecan 23Ipilimumab 23dinutuximab 21Cisplatin 21Blood Specimen Collection 21fludarabine 19Radiotherapy, Intensity-Modulated 19X-Rays 18Surgical Procedures, Operative 18abemaciclib 16Mental Status and Dementia Tests 16Granulocyte-Macrophage Colony-Stimulating Factor 16Pemetrexed 15atezolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Dianhydrogalactitol × CNS × 1 year × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT03050736 2025-09-04

Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression

Kintara Therapeutics, Inc.

Phase 2 Completed
29 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT03149575 2025-09-04

STAR-3

Kintara Therapeutics, Inc.

Phase 3 Terminated
2 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT01478178 2025-08-29

Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

Kintara Therapeutics, Inc.

Phase 1/2 Completed
55 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT02717962 2025-08-29

Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting

Kintara Therapeutics, Inc.

Phase 2 Completed
118 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡